Canada markets open in 9 hours 24 minutes

Gyre Therapeutics, Inc. (L9S.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
13.20+0.30 (+2.33%)
At close: 08:06AM CEST
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
2023-12-31
2022-12-31
2021-12-31
Total Revenue
697,770
113,450
102,290
89,587
Cost of Revenue
30,272
4,636
4,793
4,021
Gross Profit
667,498
108,814
97,497
85,566
Operating Expenses
Research Development
54,716
13,780
16,686
7,246
Selling General and Administrative
426,108
75,821
71,608
48,332
Total Operating Expenses
475,062
89,601
88,294
55,433
Operating Income or Loss
192,436
19,213
9,203
30,134
Interest Expense
264
-
299
122.3702
Total Other Income/Expenses Net
-7,883
-97,222
-517
-788.6604
Income Before Tax
189,172
-76,965
9,412
29,605
Income Tax Expense
40,274
8,515
5,098
6,168
Income from Continuing Operations
148,898
-85,480
4,314
23,437
Net Income
148,898
-92,933
2,302
23,437
Net Income available to common shareholders
148,898
-92,933
2,302
23,437
Basic EPS
1.94
-
0.03
0.31
Diluted EPS
1.94
-
0.03
0.31
Basic Average Shares
76,584
-
76,584
76,584
Diluted Average Shares
76,584
-
76,584
76,584